Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098564 | 0.78 | HPGD (0.74) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL30739535 | 0.78 | ALDH1A1 (0.68) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL7179544 | 0.76 | RAB9A (0.55) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL28249518 | 0.75 | POLB (0.67) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL102983 | 0.75 | RAB9A (0.83) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL7501801 | 0.75 | HTT (0.69) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL4103033 | 0.74 | POLB (0.56) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL2152475 | 0.74 | MAOB (0.73) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL7178708 | 0.72 | SRD5A2 (0.52) | SMN1; SMN2RAB9AALDH1A1HTTMAPT | |
| SCHEMBL21508396 | 0.72 | SMN1; SMN2 (0.75) | SMN1; SMN2RAB9AALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1055658-B1 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6395911-B1 | AND OTHER INTERMEDIATES TO THE OSTEOPOROSIS DRUG (-)CIS-6-PHENYL-5-(4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL)-5,6,7, 8-TETRAHYDRONAPHTHALENE-2-OL | PFIZER INC. | 2002-05-28 | — | — | US | disclosed |
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | CHIU CHARLES K F (US) | 2002-04-11 | — | — | US | disclosed |
| US-6323345-B1 | BROMINATING 2-BROMO-5-METHOXY-TOLUENE TO PROVIDE 1-BROMO-2-BROMOMETHYL-4-METHOXYBENZENE; DECARBOXYLATION, REACTING WITH ETHYLENE GLYCOL; REACTING WITH N-BUTYL LITHIUM AND 4-BENZYLOXY BENZONITRILE; HYDROLYSIS, HYDROGENATION | PFIZER INC. | 2001-11-27 | — | — | US | disclosed |
| US-6232476-B1 | Intermediates in a process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine | PFIZER INC. | 2001-05-15 | — | — | US | disclosed |
| EP-1055658-A2 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | Pfizer Products Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | P4HA1, PAH, DNM1 | SMN1; SMN2 814/4885RAB9A 1513/4885ALDH1A1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.